Reneo Pharmaceuticals, Inc. - מכפיל EV/Sales RPHM

The EV/Sales valuation chart on GURU.Markets illustrates the current state of Reneo Pharmaceuticals (RPHM), which is seeking a buyer after failed trials of its lead drug, retaining only its remaining capital. On GURU.Markets, this chart reflects as the baseline value. The company faces a lack of revenue and dependence on biotech trends, although the potential for global market capture of rare diseases through an intellectual monopoly remains colossal.
RPHM (Reneo Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This ratio compares the total enterprise value, including debt, to the volume of generated revenue, allowing for an assessment of the market premium per unit of sales without distortions from the capital structure. Analyzing the EV/Sales ratio for Reneo Pharmaceuticals (RPHM) is critical, as sanction restrictions and disruptions in biomaterial logistics could slow revenue growth rates, transforming current investment attractiveness into increased risks of profit shortfalls.